Antiangiogenesis: A possible treatment option for prostate cancer?

Ritchie L. Longoria; Michael C. Cox; William D. Figg

doi:10.3816/CGC.2005.n.033

Antiangiogenesis: A possible treatment option for prostate cancer?

Ritchie L. Longoria, Michael C. Cox, William D. Figg^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

With a need for effective treatment modalities in prostate cancer, angiogenesis is a likely target for the interference of tumor progression. Angiogenesis promotes the vasculature of a tumor, allowing for tumor progression and for cancer cells to metastasize and spread throughout the circulatory system. To date, there are > 20 antiangiogenic drugs undergoing preclinical and clinical investigation alone and in conjunction with other treatment options to determine the validity of antiangtogenic agents in the treatment of prostate cancer. This article reviews several aspects of antiangiogenesis and its relationship to the treatment of prostate cancer.

Original language	English
Pages (from-to)	197-202
Number of pages	6
Journal	Clinical Genitourinary Cancer
Volume	4
Issue number	3
DOIs	https://doi.org/10.3816/CGC.2005.n.033
State	Published - Dec 2005
Externally published	Yes

Keywords

Bevacizumab
Cetuximab
Marimastat
Matrix metalloproteinase
Thalidomide
Vascular endothelial growth factor

Access to Document

10.3816/CGC.2005.n.033

Cite this

@article{431b672434a3467b8f78b0772448b324,

title = "Antiangiogenesis: A possible treatment option for prostate cancer?",

abstract = "With a need for effective treatment modalities in prostate cancer, angiogenesis is a likely target for the interference of tumor progression. Angiogenesis promotes the vasculature of a tumor, allowing for tumor progression and for cancer cells to metastasize and spread throughout the circulatory system. To date, there are > 20 antiangiogenic drugs undergoing preclinical and clinical investigation alone and in conjunction with other treatment options to determine the validity of antiangtogenic agents in the treatment of prostate cancer. This article reviews several aspects of antiangiogenesis and its relationship to the treatment of prostate cancer.",

keywords = "Bevacizumab, Cetuximab, Marimastat, Matrix metalloproteinase, Thalidomide, Vascular endothelial growth factor",

author = "Longoria, {Ritchie L.} and Cox, {Michael C.} and Figg, {William D.}",

year = "2005",

month = dec,

doi = "10.3816/CGC.2005.n.033",

language = "English",

volume = "4",

pages = "197--202",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

number = "3",

}

TY - JOUR

T1 - Antiangiogenesis

T2 - A possible treatment option for prostate cancer?

AU - Longoria, Ritchie L.

AU - Cox, Michael C.

AU - Figg, William D.

PY - 2005/12

Y1 - 2005/12

N2 - With a need for effective treatment modalities in prostate cancer, angiogenesis is a likely target for the interference of tumor progression. Angiogenesis promotes the vasculature of a tumor, allowing for tumor progression and for cancer cells to metastasize and spread throughout the circulatory system. To date, there are > 20 antiangiogenic drugs undergoing preclinical and clinical investigation alone and in conjunction with other treatment options to determine the validity of antiangtogenic agents in the treatment of prostate cancer. This article reviews several aspects of antiangiogenesis and its relationship to the treatment of prostate cancer.

AB - With a need for effective treatment modalities in prostate cancer, angiogenesis is a likely target for the interference of tumor progression. Angiogenesis promotes the vasculature of a tumor, allowing for tumor progression and for cancer cells to metastasize and spread throughout the circulatory system. To date, there are > 20 antiangiogenic drugs undergoing preclinical and clinical investigation alone and in conjunction with other treatment options to determine the validity of antiangtogenic agents in the treatment of prostate cancer. This article reviews several aspects of antiangiogenesis and its relationship to the treatment of prostate cancer.

KW - Bevacizumab

KW - Cetuximab

KW - Marimastat

KW - Matrix metalloproteinase

KW - Thalidomide

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33644948640&partnerID=8YFLogxK

U2 - 10.3816/CGC.2005.n.033

DO - 10.3816/CGC.2005.n.033

M3 - Article

C2 - 16425989

AN - SCOPUS:33644948640

SN - 1558-7673

VL - 4

SP - 197

EP - 202

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 3

ER -

Antiangiogenesis: A possible treatment option for prostate cancer?

Abstract

Keywords

Access to Document

Fingerprint

Cite this